Conserved interferon-gamma signaling and decreased immune exclusion programs in responses to immune checkpoint blockade therapy CM38-RNA

Dataset ID Technology Samples
EGAD00001006282 Illumina HiSeq 2000 54

Dataset Description

We analyzed baseline and on-therapy tumor biopsies from 101 patients with advanced melanoma treated with nivolumab (anti-PD-1) alone or combined with ipilimumab (anti-CTLA-4). Analysis of whole transcriptome data showed that T cell infiltration and interferon-gamma signaling signatures corresponded most highly with clinical response to therapy, with a reciprocal decrease in cell cycle and WNT signaling pathways in responding biopsies. Clinical outcome differences were likely not due to differential melanoma cell responses to interferon-gamma, as 57 human melanoma cell lines exposed in vitro to this cytokine showed a conserved interferon-gamma transcriptome response unless they had mutations that precluded signaling from the interferon-gamma receptor. Therefore, the magnitude of the antitumor T cell response and the corresponding downstream interferon-gamma signaling are the main drivers of clinical response or resistance to immune checkpoint blockade therapy.

Data Use Conditions


See further information on Data Use Conditions

Label Code Version Modifier
disease specific research DUO:0000007 2019-01-07 MONDO:0004992; MONDO:0005105